aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize cancer treatment, Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies for immune modulation. The company's core vision is to create or break immune tolerance to treat various diseases effectively. Batu Biologics is currently advancing two flagship products, Immstem and Vallovax, both in the preclinical stages of drug development. The company has also filed two provisional patents in the field of cancer immunotherapy, aiming to expand its intellectual property significantly.
Notable figures associated with Batu Biologics include experts in oncology and immunotherapy, although specific names are not provided. The company has garnered attention for its innovative approach to cancer treatment, particularly through its development of allogeneic cell therapies. Key achievements include the progression of its flagship products and the filing of provisional patents, which underscore its potential impact on the biopharmaceutical industry. Batu Biologics continues to make strides in preclinical research, positioning itself as a promising player in the field of cancer immunotherapy.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Cell Therapies
Technology
Biotech
Tags
Healthtech
Customer Type(s)
Enterprise, Government
Geographic Exposure
Americas
When was Batu Biologics founded?
Batu Biologics was founded in 2013.
Where is Batu Biologics’s headquarters located?
Batu Biologics’s headquarters is located in San Diego, CA, US.
When was Batu Biologics’s last funding round?
Batu Biologics’s most recent funding round was for $1.3M (USD) in December 2017.
How many employees does Batu Biologics have?
Batu Biologics has 6 employees as of Feb 5, 2024.
How much has Batu Biologics raised to-date?
As of July 05, 2023, Batu Biologics has raised a total of $2.8M (USD) since Dec 25, 2017.
Add Comparison
Total Raised to Date
$2.8M
USD
Last Update Dec 25, 2017
Last Deal Details
$1.3M
USD
Dec 25, 2017
Equity Crowdfunding
Total Employees Over Time
6
As of Feb 2024
Batu Biologics Address
9255 Towne Centre Dr
San Diego,
California
92121
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts